Interní Med. 2010; 12(10): 487-489

Current perspective on indications for administering the combination of ACEI and sartans

prof.MUDr.Jiří Vítovec, CSc., FESC1, prof.MUDr.Jindřich ©pinar, CSc., FESC2
1 I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně
2 Interní kardiologická klinika LF MU a FN, Brno

The article deals with the pathophysiological basis for the combination of angiotenzin-converting enzyme (ACE) inhibitors and angiotenzin

II type 1 receptor blockers (sartans) in the treatment of hypertension, heart failure and conditions after myocardial infarction

and in the secondary prevention of coronary artery disease. The risks of combining these substances are discussed, particularly in terms

of recent critical literature reviews of this combination, and a very careful consideration of the indications for coadministration of ACE

inhibitors and sartans is emphasised.

myocardial infarction, coronary artery disease.

Keywords: angiotenzin-converting enzyme inhibitors, angiotenzin II type 1 receptor blockers (sartans), hypertension, heart failure,

Published: November 15, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinar J. Current perspective on indications for administering the combination of ACEI and sartans. Interní Med. 2010;12(10):487-489.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bultas J. Osa renin-angiotenzin-aldosteron - půl století od objasnění funkce a stále nová překvapení. Remedia 2008; 18: 120-129.
    2. Opie LH, Gersh JB, et al. Drug for heart. 7th ed. Philadelphia: Elsevier, 2009: 502 p.
    3. Vítovec J, ©pinar J, et al. Farmakoterapie kardiovaskulárních onemocnění. 2. vyd. Praha: Grada, 2004: 248 s.
    4. Azizi M, Ménard J. Combined blockade of the renin-angiotenzin system with angiotenzin-converting enzyme inhibitors and angiotenzin II type 1 receptor antagonists. Circulation 2004; 109: 2492-2499. Go to original source... Go to PubMed...
    5. ©pinar J, Vítovec J. Indikace blokátorů receptorů 1 pro angiotenzin II v roce 2002. Interní Med Prax 2002; 4: 164-168.
    6. Bultas J. Blokátory receptorů AT1 ve světle medicíny zaloľené na důkazech. JACC-CZ 2003; 4: 247-248.
    7. Linhart A. ACE-inhibitory a blokátory AT1 receptorů aktuální v kardiovaskulární farmakoterapii. Kardiol Rev (KF) 2003: 4: 25-30.
    8. 2007 ESH-ESC Practice Guidelines for the management of arterial hypertension. ESH-ESC Task Force on the management of Arterial Hypertension. J Hypertens 2007; 25: 1751-1762.
    9. Widimský J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Cor Vasa 2008; 50: K5-K22.
    10. Azizi M, Linhart A, Alexander J, et al. Pilot study of combined blockade of the renin-angiotenzin system in essential hypertensive patients. J Hypertens 2000; 18: 1139-1147. Go to original source... Go to PubMed...
    11. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotenzin II receptor blocker and angiotenzin converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124. Go to original source... Go to PubMed...
    12. Doulton TWR, He FJ, MacGregor GA. Systematic Review of Combined Angiotenzin-Converting Enzyme Inhibition and Angiotenzin Receptor Blockade in Hypertension. Hypertension 2005; 45; 880-886. Go to original source... Go to PubMed...
    13. The ONTARGET investigators: telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
    14. Flather MD, Yusuf S, Kober L, et al. Long term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-1581. Go to original source... Go to PubMed...
    15. Widimský J. Výsledky studie léčby srdečního selhání ValHeFT. Cor Vasa 2001; 43: 110-112.
    16. Vítovec J, ©pinar J. Mohou blokátory receptorů pro angiotenzin II (AIIA) nahradit v léčbě srdečního selhání inhibitory ACE? Cor Vasa 2003; 45: 169-170.
    17. McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotenzin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771. Go to original source... Go to PubMed...
    18. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. for VALIANT Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906. Go to original source... Go to PubMed...
    19. Messerli FH. The Sudden Demise of Dual Renin-Angiotenzin System Blockade or the Soft Science of the Surrogate End Point. J Am Coll Cardiol 2009; 53: 468-470. Go to original source... Go to PubMed...
    20. Sipahi I, Debanne SM, Rowland DY, et al. Angiotenzin receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; published online June 14. DOI: 10.1016/S1470-2045 (10)70106-6. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.